Many categories of hypoglycemic agents are presently used in the management of type 2 diabetes, which acts through a diverse mechanism of actions, such as in promoting insulin secretion, minimizing insulin resistance, or improving insulin penetration into the cells [3]. The gene discussed is INS; the disease is Insulin resistance.